Tilray Brands (NASDAQ:TLRY) Stock, Quote.Headers.trade-ideas

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.

Tilray Brands

medical marijuana (Roxana Gonzalez on Shutterstock)

Cannabis

News

Retail Sales

TLRY

TSX:TLRY

Tilray Medical announced on Wednesday the launch of Redecan EU-GMP certified medical cannabis products in Australia.

Cannabis Giant Tilray Expands Medical Marijuana Portfolio With Redecan Launch In Australia

finance and marijuana (Kindel Media by Pexels)

Financing

Tilray Brands agreed to acquire from DDH a promissory note for $23.8 million payable by 1974568 Ontario Limited.

Tilray Acquires $23.8M Promissory Note In Deal With Double Diamond On Heels Of Brewery Acquisition

Europe Euro rain Cannabis (M.KOS and MVelishchuk on Shutterstock)

Education

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

PCLOF

TSX:WEED

WEED

The Czech Republic could be missing out on hundreds of millions of euros annually as the governing coalition remains persistent in avoiding establishing a regulated marijuana market. That&#39;s according to the findings of a comprehensive study examining the possible costs and benefits of various cannabis reform models being proposed nationwide.

This European Country Could Lose $242M A Year If It Doesn&#39;t Regulate Its Marijuana Market, Study Finds

Tilray Brands Inc

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 1491.67% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/BMMJ">Body and Mind</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed up 42.26% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed up 22.73% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 18.97% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 16.58% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed up 11.52% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 4.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 3.95% at $0.15</li>
<li><a href="https://www.benzinga.com/quote/OGI">OrganiGram Holdings</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) shares closed up 3.26% at $1.80</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">Cansortium</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 3.05% at $0.17</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 61.70% at $19.51</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 31.03% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 18.03% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed down 13.85% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 10.27% at $2.95</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed down 10.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed down 9.18% at $0.85</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 7.76% at $0.22</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 5.76% at $1.31</li>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed down 5.50% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed down 5.12% at $2.04</li>
<li><a href="https://www.benzinga.com/quote/EAST">Eastside Distilling</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) shares closed down 4.94% at $0.51</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed down 4.76% at $1.99</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed down 4.59% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/CPHRF">Cipher Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>) shares closed down 3.53% at $10.67</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 3.38% at $1.72</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 3.33% at $0.47</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 3.15% at $0.26</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed down 3.02% at $11.04</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Markets

Movers

BBRRF

BLGVF

BMMJ

CBDY

CNTMF

CPHRF

CRBP

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CXXIF

EAST

ELLXF

FFNTF

FUAPF

GRWG

ITHUF

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LMLLF

MRMD

NWVCF

OILFF

RMHB

SNDL

TCNNF

UGRO

XXII

YCBD

Cannabis Stock Movers For September 20, 2024

Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#TSX">TLRY</a>) announced on Wednesday the launch of Redecan EU-GMP certified medical <a href="https://www.benzinga.com/topic/australia">cannabis products in Australia</a>.
What Happened: The following&nbsp;Redecan&nbsp;products are now available for medical cannabis patients in&nbsp;Australia, including:
<ul>
<li>Redecan PC THC28 Purple Churro – 15g</li>
<li>Redecan SA THC28 Space Age Cake – 15g</li>
</ul>
Why It Matters: Denise Faltischek, chief strategy officer and head of international at Tilray Brands, praised the move.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/22/08/28597648/tilrays-cbd100-approved-for-clinical-trials-in-australia-and-new-zealand-by-the-natural-health-s">Tilray&#8217;s CBD100 Approved For Clinical Trials In Australia And New Zealand By The Natural Health Science Foundation</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
"The launch of Redecan further expands our medical cannabis portfolios alongside our current Tilray and Broken Coast offerings, as we continue our mission of empowering patients and healthcare practitioners to find the optimal therapeutic solutions," Faltischek said.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18084431/ccc-oct-24-banner__1_-26.gif" alt="" class="wp-image-553913" /></a></figure>
Jonathan Trodden, director at Tilray Medical Australia, agrees: "We are proud to launch Redecan in Australia and further strengthen our ongoing commitment to providing patients with a consistent, accessible supply of premium quality medical cannabis to choose from.&#8221;
Tilray has been present in Australia for years. In 2022, the company launched a new medical cannabis e-learning platform for healthcare providers, built on the importance of understanding the benefits derived <a href="https://www.benzinga.com/markets/cannabis/22/01/25204825/tilray-expands-medical-marijuana-product-offering-in-australia-launches-cannabis-e-learning-plat">from medical cannabis use</a>. This effort followed Tilray&#8217;s successful introduction of multiple medical cannabis workshops across Australia and New Zealand, educating hundreds of healthcare practitioners in 2021.
Price Action: Tilray's shares traded 0.51% higher at $1.8193 per share during the pre-market session on Wednesday morning.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/03/37706111/weed-giants-tilray-and-curaleaf-ramp-up-presence-in-europe-heres-why">Weed Giants Tilray And Curaleaf Ramp Up Presence In Europe, Here&#8217;s Why</a></li>
</ul>

Tilray Medical Announced The Launch Of Redecan EU-GMP Certified Medical Cannabis Products In Australia

Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) agreed to acquire a promissory note from Ontario-based Double Diamond Holdings Ltd (DDH) for $23.8 million, according to a regulatory filing.
DDH is a joint venture with Aphria Inc., Tilray's direct and wholly-owned subsidiary, in Aphria Diamond.
In return, Tilray issued 13,217,588 shares of its common stock at $0.0001 per share to DDH.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/17095856/ccc-oct-24-banner__1_-1-10.gif" alt="" class="wp-image-551931" /></a></figure>
The company said no underwriter took part in the offer and sale of the consideration shares, and no commission or other remuneration was paid or given directly or indirectly in connection with the deal.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
Read Also:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40036301/tilray-should-be-a-long-term-holding-in-any-global-portfolio-of-cannabis-stocks-say"> ‘Tilray Should Be A Long-Term Holding In Any Global Portfolio Of Cannabis Stocks,&#8217; Says Analyst</a>
<h3 class="wp-block-heading">Tilray's Craft Beer Business</h3>
The news comes on the heels of Tilray's announcement that it has completed the <a href="https://www.benzinga.com/markets/cannabis/24/08/40365052/billion-dollar-cannabis-firm-buys-a-brewery-four-actually-in-canadas-backyard">previously announced</a> acquisition of Atwater Brewery, from Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>). Atwater Brewery was one of four craft breweries Tillray previously said it would acquire. The medical cannabis giant acquired Hop Valley Brewing Company, Terrapin Beer Co., and Revolver Brewing, in early September.
The acquisition bolstered Tilray's leadership position in the U.S. craft beer market as the 5th largest craft brewer in the country and the top craft brewer in the Pacific Northwest and Georgia. Tilray is based in Canada.
Known for brands like SweetWater Brewing and Montauk Brewing Company, Tilray earlier said it expects a 30% growth in its <a href="https://www.benzinga.com/markets/cannabis/23/09/34579077/tilrays-beer-business-expands-nationally-starting-in-this-state">beer business from this acquisition.</a>
Irwin D. Simon, the company's chairman and CEO, praised the move. &#8220;This strategic acquisition creates additional growth opportunities for our global beverage business, which reinforces our commitment to enhancing shareholder value,&#8221; he said.
Price Action: Tilray&#8217;s shares traded 1.11%% higher at $1.8199 per share at the time of writing on Tuesday morning.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/06/39539050/is-tilrays-2b-valuation-just-the-beginning-analyst-sees-10b-market-opportunity-initiates-coverag">Is Tilray Really Worth $2B? Analysts See Path To $10B Market Opportunity</a></li>
</ul>
Photo: Courtesy of Kindel Media by Pexels

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed up 38.20% at $5.91</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 20.09% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 13.92% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 13.33% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed up 7.28% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/EAST">Eastside Distilling</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) shares closed up 6.11% at $0.59</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed up 4.32% at $10.78</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 4.04% at $1.40</li>
<li><a href="https://www.benzinga.com/quote/GENE">Genetic Technologies</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENE#NASDAQ">GENE</a>) shares closed up 3.62% at $0.82</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed up 3.45% at $1.80</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed down 28.57% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 20.05% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed down 15.10% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 14.29% at $0.0006</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 9.09% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed down 8.27% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 8.24% at $0.32</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 5.60% at $2.35</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 3.46% at $53.88</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GENE

GNLN

GTBIF

KAYS

TGIFF

Marijuana Stock Movers For September 16, 2024

The Czech Republic could be missing out on hundreds of millions of euros annually as the governing coalition remains persistent in avoiding establishing a regulated marijuana market. That's according to the findings of a comprehensive study examining the possible costs and benefits of various cannabis reform models being proposed nationwide.
<h3 class="wp-block-heading">What Happened</h3>
The researchers from the Faculty of Business Economics at the University of Prague concluded that a &#8220;comprehensive model,&#8221; incorporating self-cultivation, cannabis clubs and a fully commercial market, could result in "total net social benefits of CZK 5.5 billion (218 million euros; $242 million) per year," <a href="https://businessofcannabis.com/new-study-backs-full-cannabis-legalisation-in-czech-republic-projecting-czk-5-5bn-in-social-benefits-annually/">reported</a> Business of Cannabis.
The study was published on Thursday, Sept. 12, by the University of Prague. It analyzed each of the cannabis reform models proposed by former National Drug Coordinator Jindřich Vobořil.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16093721/ccc-oct-24-banner__1_-22.gif" alt="" class="wp-image-549705" /></a></figure>
Vobořil left his position this summer, but he continued taking part in the development of addiction policies in the country as an <a href="https://www.benzinga.com/markets/cannabis/24/07/39915786/leaked-document-reveals-czechias-plans-for-cannabis-legalization">independent expert.</a> He previously completed two separate versions of the measure to legalize cannabis.
Vobořil's legislation, which includes commercial sales, seeks to set up a cannabis market <a href="https://www.benzinga.com/markets/cannabis/24/07/39773667/leaked-documents-czech-republic-plans-to-set-up-legal-recreational-cannabis-market">much like that in Canada and certain US states.</a> The other measure mimics Germany's current cannabis framework, with legal home cultivation and cannabis social clubs.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40626067/full-cannabis-legalization-not-yet-off-the-table-in-czech-republic-some-lawmakers-want-only-home">Full Cannabis Legalization Not Yet Off The Table In Czech Republic, Some Lawmakers Want Only Home Grow</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Which Legalization Model Is Most Economically Advantageous?</h3>
That said, the study suggested that legalizing only self-cultivation would yield a net social benefit of CZK 1.2 billion annually and CZK 16.5 billion over the first 11 years. Moreover, putting cannabis clubs into the equation would result in CZK 1.5 billion per year and CZK 20.8 billion over 11 years in social benefits.
However, the highest returns would come from the comprehensive model, featuring a regulated market alongside self-cultivation and clubs, which is projected to deliver CZK 5.5 billion per year and CZK 77.2 billion over 11 years in social benefits.
"The conclusions are very simple,&#8221; Patrik Sieber, one of the study's authors, said. &#8220;All evaluated options appear to be socially and financially more beneficial for public budgets than maintaining the status quo.&#8221;
<h3 class="wp-block-heading">These Cannabis Operators Could Benefit From Policy Change</h3>
In the meantime, cannabis operators have been strengthening their market presence in the European country.
Curaleaf International, part of Curaleaf Holdings Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>), already present in the European market, opted to expand in the Czech Republic in March, via a new <a href="https://www.benzinga.com/markets/cannabis/24/03/37706111/weed-giants-tilray-and-curaleaf-ramp-up-presence-in-europe-heres-why">supply agreement with Astrasana Pharma s.r.o.</a> Under that deal, Curaleaf International's EU-GMP flower was made available to patients via Pilulka Pharmacy, a healthcare provider in the region.
PharmaCielo Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PCLOF#OTC">PCLOF</a>)'s first shipment of THC-dominant dried cannabis flower to a customer in the Czech Republic <a href="https://www.benzinga.com/markets/cannabis/22/09/28882197/pharmacielo-ships-dried-cannabis-flower-to-the-czech-republic-expanding-its-exports-to-eu">made headlines in 2022.</a>
In 2023, the medical cannabis division of Canadian giant Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) expanded its European footprint across the Czech Republic through a new export and distribution <a href="https://www.benzinga.com/markets/cannabis/23/10/35162207/canopy-growth-shares-up-slightly-in-pre-market-trading-on-eu-gmp-certification-news">partnership with Cansativa Group.</a>
Additionally, Canopy Growth Corporation (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WEED#TSX">WEED</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>)&#8217;s medical brands already service European medical markets in Germany, the Czech Republic and Poland as well as Asia-Pacific markets including <a href="https://www.benzinga.com/markets/cannabis/23/10/35162207/canopy-growth-shares-up-slightly-in-pre-market-trading-on-eu-gmp-certification-news">Australia and New Zealand</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/06/39442869/2-9b-european-cannabis-market-a-strategic-blueprint-for-cross-border-transportation-logistics">$2.9B European Cannabis Market: A Strategic Blueprint For Cross-Border Transportation Logistics</a></li>
</ul>

This European Country Could Lose $242M A Year If It Doesn't Regulate Its Marijuana Market, Study Finds

Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) confirmed Thursday it has completed the <a href="https://www.benzinga.com/markets/cannabis/24/08/40365052/billion-dollar-cannabis-firm-buys-a-brewery-four-actually-in-canadas-backyard">previously announced</a> acquisition of Atwater Brewery, from Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>).
&#8220;Atwater Brewery is a renowned craft brewery with a rich history and a loyal following in Michigan," said Irwin D. Simon, chairman and chief executive officer of Tilray Brands. "This acquisition expands our reach in the Great Lakes region and further strengthens our position in the craft beer industry. We are excited to welcome Atwater Brewery to Tilray Brands and are committed to leveraging our expertise and resources to drive growth, expand distribution, and provide beer lovers with access to Atwater&#8217;s exceptional brews."
TD Securities acted as financial advisor, and DLA Piper LLP (US) acted as external legal counsel to Tilray Brands.
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out
The Atwater Brewery acquisition comes on the heels of finalized purchases of craft breweries Hop Valley Brewing Company, Terrapin Beer Co., and Revolver Brewing, also from Molson.
Over the last several months, Tilray, <a href="https://www.benzinga.com/markets/cannabis/24/06/39539050/is-tilrays-2b-valuation-just-the-beginning-analyst-sees-10b-market-opportunity-initiates-coverag" target="_blank" rel="noreferrer noopener">valued</a> at $2 billion, has been expanding its U.S. brewery business but is not giving up on cannabis. In August, it <a href="https://www.benzinga.com/markets/cannabis/24/08/40510926/tilray-is-not-giving-up-on-cannabis-ramps-up-its-canadian-portfolio-on-heels-of-buying-four-us-b">released its latest small-batch flower strain</a>, Milk &amp; Cookies, under its premium cannabis brand Broken Coast, and in September, it published the results of a study focused on cannabis as a potential treatment for pain management and <a href="https://www.benzinga.com/markets/cannabis/24/09/40774179/cannabinoid-treatment-significantly-reduces-fibromyalgia-pain-and-improves-quality-of-life-new-t">other fibromyalgia-associated symptoms</a>.
Moreover, the Canadian cannabis giant is also working on expanding its medical marijuana business globally and has <a href="https://www.benzinga.com/markets/cannabis/24/08/40325566/these-3-cannabis-companies-hold-cultivation-licenses-in-germany-a-1-8b-market-opportunity" target="_blank" rel="noreferrer noopener">already obtained a cultivation license</a> in Germany, whose market is <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37896976/cannabis-stocks-set-to-dominate-germanys-new-market-a-surge-in-demand-meets-establi" target="_blank" rel="noreferrer noopener">projected</a> to reach a valuation of approximately €1.7 billion ($1.86 billion) by 2025​.
Tilray Brands' beverage portfolio includes famed craft beer, spirits and non-alcohol beverage brands such as SweetWater Brewing Company, Montauk Brewing Company, Alpine Beer Company, Green Flash Brewing Company, Shock Top, Breckenridge Brewery, Breckenridge Distillery, Blue Point Brewing Company, 10 Barrel Brewing Company, Redhook Brewing Company, Widmer Brothers Brewing, Square Mile Cider Company, HiBall Energy, Happy Flower CBD along with Canada&#8217;s top recreational cannabis and THC beverage brands Mollo and XMG.
Price Action: Tilray shares closed Thursday's market session 1.16% lower at $1.70 per share.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/06/39539050/is-tilrays-2b-valuation-just-the-beginning-analyst-sees-10b-market-opportunity-initiates-coverag">Is Tilray Really Worth $2B? Analysts Sees Path To $10B Market Opportunity</a></li>
</ul>
Photo: Courtesy of Lucas via Pexels

Billion-Dollar Marijuana Giant Buys Another Brewery From Molson Coors, Expands Great Lakes Footprint

Tilray Brands's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NYSE">TLRY</a>) short percent of float has fallen 6.2% since its last report. The company recently reported that it has 101.55 million shares sold short, which is 12.1% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.19 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tilray Brands Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726166716_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tilray Brands has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Tilray Brands's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tilray Brands's peer group average for short interest as a percentage of float is 19.42%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

(TLRY) - Analyzing Tilray Brands's Short Interest

SNDL Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) announced on Tuesday that Taranvir &#8220;Tank&#8221; Vander, president of its Liquor Division, is stepping down after two decades of leadership in the liquor industry. Vander, who began his career as a liquor store manager in the early 2000s, is retiring to pursue new opportunities.
In 2013, Vander founded Ace Liquor Corporation, expanding it to 15 stores. In 2019, he joined forces with Alcanna Inc., helping it become one of Canada's largest liquor retailers. Zachary George, CEO of SNDL, thanked Vander for his contributions. "We want to thank Tank for his exceptional leadership and wish him continued success in his future endeavors."
Navroop Sandhawalia, VP of finance for Liquor Retail at SNDL, <a href="https://www.prnewswire.com/news-releases/sndl-announces-departure-of-liquor-segment-president-302244048.html#:~:text=CALGARY%2C%20AB%2C%20Sept.%2010,SNDL%20to%20pursue%20new%20opportunities">will take over</a> as interim president of the liquor division while the company searches for a permanent replacement.
Get Benzinga&#8217;s exclusive analysis and top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.
<h3 class="wp-block-heading">SNDL Stock Performance Compared To Other Canadian Cannabis Companies</h3>
After the market closed on Tuesday, September 10, 2024, SNDL experienced a slight dip in its stock price, closing at $2.10, down 0.47%. Trading volume for SNDL reached 1,697,281 shares, reflecting continued investor activity as the company transitions leadership in its Liquor Division.
In comparison, other notable <a href="https://www.benzinga.com/topic/canada-cannabis">Canadian cannabis stocks</a> also saw mixed results:
<ul>
<li>Aurora Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) closed at $5.55, down 1.56%, with 568,615 shares traded. Despite a lower percentage drop than SNDL, Aurora's stock showed greater volatility with a day high of $5.90 and a low of $5.55.</li>
<li>OrganiGram Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) fared slightly better, closing at $1.83, up 1.1%. The stock saw a trading volume of 297,194 shares, indicating moderate investor interest.</li>
<li>Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) closed at $1.69, down 0.59%, with a significant trading volume of 18,592,650 shares, reflecting heightened activity compared to other stocks.</li>
<li>High Tide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>) showed positive momentum, increasing by 3.3% to close at $2.13, with 447,671 shares traded, positioning it among the stronger performers in the sector today.</li>
<li>Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) closed at $4.84, down 1.03%, with a volume of 2,777,417 shares. Despite the decline, Canopy saw considerable trading activity, suggesting continued investor engagement.</li>
</ul>
Overall, <a href="https://www.benzinga.com/markets/cannabis/24/08/40631613/sndl-wins-bid-for-indiva-secures-major-deal-to-boost-cannabis-edibles-market-share-in-canada">SNDL's performance </a>was relatively stable compared to its peers, with many Canadian cannabis stocks experiencing minor fluctuations throughout the trading day. The trading volumes across the sector reflected ongoing interest but no significant market shifts following the day&#8217;s developments.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40783919/cannabis-flower-no-thanks-canadians-shift-to-pre-rolls-vapes-as-market-eyes-c-5-47b">Cannabis Flower? No, Thanks: Canadians Shift To Pre-Rolls &amp; Vapes As Market Eyes C$5.47B</a>

Management

 CGC

HITI

Last Call For SNDL's Liquor President: Stock On The Rocks Amid Leadership Changes

The latest equity research report from Pablo Zuanic of Zuanic &amp; Associates highlights key trends in Canada's cannabis market, noting a deceleration in recreational sales growth.
Data from StatCan reveals that sales for 2Q24 were down 4% year-over-year (YoY), contributing to a 1.3% decline year-to-date (YTD) compared to 14% growth in 1H23. In contrast, Hifyre data shows a 6% YTD growth through August.
If annualized, this growth would project a total<a href="https://www.benzinga.com/topic/canada-cannabis"> recreational market</a> size of C$5.47 billion for calendar year 2024, translating to US$102 per capita.
Get Benzinga&#8217;s exclusive analysis and top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.
<h3 class="wp-block-heading">Market Share Shifts Among Top Players</h3>
<a href="https://www.benzinga.com/topic/pablo-zuanic">Zuanic&#8217;s report </a>highlights notable shifts in market share among the top licensed producers (LPs). Tilray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>), once a dominant player, saw its share drop by 1.5 percentage points to 9.6% in August, continuing its decline over recent quarters. Decibel (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/DB#TSXV">DB</a>) also experienced a decline, dropping 0.9 percentage points to 5.2%.
Meanwhile, Village Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) experienced strong growth, increasing its market share to 7.9%, up from 6.1% a year ago, representing a 34% year-over-year growth. Similarly, Cronos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) and Organigram (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) posted gains, with Cronos maintaining a steady 5.3% share (up 24% YoY), and Organigram growing its market share to 7.2%, up from 6.6% a year ago, reflecting 15% (YoY) growth.
Additionally, Auxly (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) and Cannara Biotech (unlisted) gained 0.5 points each, reaching 5.2% and 3.4% market shares, respectively.
Here is a breakdown of the major players:
<ul>
<li>Village Farms: sales grew +34% YoY, holding a 7.9% market share in August (up from 6.1% a year ago).</li>
<li>Cronos: +24% YoY growth in sales, maintaining a 5.3% share, consistent with previous quarters.</li>
<li>Organigram: +15% YoY growth in sales, with a market share of 7.2% in August, up from 6.6% a year ago.</li>
<li>Tilray: -20% YoY decline in sales, with a 9.6% market share in August, down from 10.1% earlier in the quarter.</li>
<li>Decibel: -25% YoY decline in sales, holding a 5.3% market share, down from 7.4% a year ago.</li>
</ul>
<h3 class="wp-block-heading">Format Preferences Continue To Evolve</h3>
The Canadian cannabis market is shifting towards newer product formats, with some segments outperforming others. Flower remains the largest category, accounting for 36% of sales in June-August 2024, down from 41% in 1Q23 and 57% in 1Q21. This decline reflects changing consumer preferences, as <a href="https://www.benzinga.com/markets/cannabis/24/06/39508155/900-pre-rolls-per-hour-upgrade-from-manual-to-automatic-speeds-up-joint-production-enhances-marg">pre-rolls</a> and vapes gain market share.
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34625368/nasa-precision-meets-cannabis-roi-pre-rolled-infusion-robots-revolutionizing-indust">Pre-rolls</a> now represent 34% of total sales, up from 27% in 1Q23 and 17% in 1Q21. The segment grew 11% year-over-year (YoY) in the June-August period, driven by consumer demand for convenience. Decibel leads with a 10.4% share, though it fell to 9.7% in August. Tilray holds 8.3%, and Organigram has 6.4%.
<a href="https://www.benzinga.com/general/biotech/24/08/40341814/tony-starks-choice-vape-synergy-innovations-strategic-move-to-restore-brands-identity-lead-market">Vapes </a>account for 16% of sales, up from 15% in 1Q22 and 14% in 1Q21, supported by 8% yoy growth. Motif Labs leads with 20.6%, followed by Auxly (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) at 12.4%, up from 10.7% in 2Q24.
Other formats, like concentrates, edibles, beverages, and oils, hold smaller shares. Concentrates and edibles each represent 5%, while <a href="https://www.benzinga.com/topic/cannabis-beverages">beverages </a>and oils account for 2% each. Concentrates grew 5% YoY, while edibles declined by 5%. Beverages saw a 6% YoY increase, indicating gradual consumer adoption.
Read Next: S<a href="https://www.benzinga.com/markets/cannabis/24/08/40631613/sndl-wins-bid-for-indiva-secures-major-deal-to-boost-cannabis-edibles-market-share-in-canada">NDL Wins Bid For Indiva, Secures Major Deal To Boost Cannabis Edibles Market Share In Canada</a>

Analyst Color

Market Summary

Analyst Ratings

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CRON

TSXV:DB

Cannabis Flower? No, Thanks: Canadians Shift To Pre-Rolls & Vapes As Market Eyes C$5.47B

Former President Donald Trump announced on Sunday night that, if re-elected, he would reschedule cannabis and support banking reforms for the marijuana industry. He also confirmed his support for Florida's Amendment 3, which would legalize recreational cannabis in the state. Trump's <a href="https://www.benzinga.com/markets/cannabis/24/09/40774795/trump-says-hell-reschedule-cannabis-if-elected-backs-marijuana-banking-reform-and-floridas-amend">comments</a> sparked a reaction in the cannabis stock market on Monday.
Get Benzinga's exclusive analysis and top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h3 class="wp-block-heading">Stocks Reaction</h3>
<ul>
<li>Trulieve Cannabis (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>): The price at market close was $10.99 with a change of +$1.28 (+13.18%). Trading volume reached 707,392, with a market cap of $2.06 billion.</li>
<li>Green Thumb Industries (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>): The price at market close was $10.66 with a change of +$1.02 (+10.58%). Trading volume hit 473,092, with a market cap of $2.52 billion.</li>
<li>Curaleaf Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>): The price at market close was $3.10 with a change of +$0.26 (+9.15%). Trading volume reached 639,920, and the market cap stood at $2.09 billion.</li>
<li>Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>): The price at market close was $4.86 with a change of +$0.38 (+8.54%). Trading volume was 6,041,892, with a market cap of $412 million.</li>
<li>Sundial Growers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>): The price at market close was $2.14 with a change of +$0.16 (+8.08%). Trading volume hit 1,946,306, and the market cap was $530 million.</li>
<li>Aurora Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>): The price at market close was $5.80 with a change of +$0.39 (+7.25%). Trading volume was 1,136,294, with a market cap of $317 million.</li>
<li>Cronos Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>): The price at market close was $2.21 with a change of +$0.07 (+3.27%). Trading volume reached 1,448,055, with a market cap of $847 million.</li>
<li>HEXO Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEXO#NASDAQ">HEXO</a>): The price at market close was $1.35 with a change of +$0.05 (+3.85%). Trading volume was 1,215,840, with a market cap of $401 million.</li>
<li>AdvisorShares Pure US Cannabis ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>): The price at market close was $7.16 with a change of +$0.75 (+11.70%). Trading volume hit 13,998,304.</li>
<li>Innovative Industrial Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>): The price at market close was $122.69 with a change of +$2.02 (+1.67%). Trading volume was 90,181, with a market cap of $3.42 billion.</li>
<li>GrowGeneration (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>): The price at market close was $1.92 with a change of +$0.05 (+2.96%). Trading volume hit 454,306, and the market cap was $110 million.</li>
<li>Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>): The price at market close was $52.48 with a change of +$2.43 (+4.87%). Trading volume was 153,424, with a market cap of $630 million.</li>
<li>AdvisorShares Pure Cannabis ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOLO#NYSE">YOLO</a>): The price at market close was $3.35 with a change of +$0.21 (+6.69%). Trading volume reached 37,519.</li>
<li>Scotts Miracle-Gro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>): The price at market close was $67.62 with a change of -$0.20 (-0.29%). Trading volume reached 323,540, with a market cap of $3.85 billion.</li>
<li>Village Farms International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>): The price at market close was $1.01 with a change of +$0.01 (+1.02%). Trading volume hit 459,136, and the market cap was $113 million.</li>
<li>Trees (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CANN#OTC">CANN</a>): The price at market close was $0.042 with a change of -$0.012 (-22.22%). Trading volume was 118,407.</li>
<li>Medical Marijuana (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MJNA#OTC">MJNA</a>): The price at market close was $0.001 with no change. Trading volume hit 9,393,761, with a market cap of $5.68 million.</li>
<li>OrganiGram Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>): The price at market close was $1.83 with a change of +$0.08 (+4.29%). Trading volume was 348,054, with a market cap of $186 million.</li>
<li>High Tide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>): The price at market close was $2.12 with a change of +$0.16 (+8.16%). Trading volume hit 648,008, with a market cap of $162 million.</li>
<li>Planet 13 Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PLNHF#OTC">PLNHF</a>): The price at market close was $0.96 with no significant change. Trading volume was 275,004.</li>
<li>Cresco Labs (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>): The price at market close was $1.74 with a change of +$0.13 (+7.74%). Trading volume hit 438,517, with a market cap of $565 million.</li>
</ul>
<h3 class="wp-block-heading">Highs And Lows In 2024&nbsp;</h3>
The cannabis market has experienced several significant stock movements in recent months. On April 30, 2024, stocks soared after the DEA announced plans to reschedule cannabis to Schedule III, with Canopy Growth <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38536953/cannabis-stocks-react-to-dea-rescheduling-canopy-aurora-surge-tilray-wm-tech-hold-s">jumping</a> by 78.8% and Aurora Cannabis rising 46%. 
However, two weeks ago, following the DEA's decision to delay its final ruling, the sector saw a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40580306/cannabis-stocks-plummet-by-up-to-16-on-dea-rescheduling-delay-could-this-be-the-buy">sharp decline</a>, with Curaleaf falling 15.68% and Green Thumb Industries dropping 10.15%. In contrast, Monday's gains following Trump's support for Amendment 3 were more modest, with a mean growth of 4.31%, suggesting a recovery but not on the same scale as the April surge.
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/40776937/trump-joins-millions-of-americans-who-support-rescheduling-cannabis-weed-industry-responds-to-fo">Trump &#8216;Joins Millions Of Americans&#8217; Who Support Rescheduling Cannabis: Weed Industry Responds To Former Pres&#8217; News</a>

Politics

ETFs

CANN

CRLBF

HEXO

IIPR

MJNA

MSOS

PLNHF

YOLO

Cannabis Stocks React To Trump's Marijuana Comments: See Which Ones Posted Solid Gains

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 40.59% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed up 40.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed up 16.67% at $0.33</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed up 12.00% at $0.25</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed up 11.11% at $0.18</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 11.06% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed up 10.53% at $2.09</li>
<li><a href="https://www.benzinga.com/quote/CNPOF">RIV Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>) shares closed up 10.31% at $0.14</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 10.31% at $0.17</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed up 10.04% at $4.85</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed up 9.86% at $3.11</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed up 8.36% at $1.75</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">Cansortium</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 7.66% at $0.18</li>
<li><a href="https://www.benzinga.com/quote/ACB">Aurora Cannabis</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) shares closed up 7.39% at $5.76</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed up 6.06% at $2.12</li>
<li><a href="https://www.benzinga.com/quote/OGI">OrganiGram Holdings</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) shares closed up 5.71% at $1.82</li>
<li><a href="https://www.benzinga.com/quote/BMMJ">Body and Mind</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed up 5.45% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed up 5.34% at $52.71</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed up 4.94% at $1.70</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed up 4.30% at $1.93</li>
<li><a href="https://www.benzinga.com/quote/CRON">Cronos Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) shares closed up 3.74% at $2.21</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed up 3.64% at $5.19</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed up 3.22% at $10.81</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CWWBF">Plant Based Investment</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWWBF#OTC">CWWBF</a>) shares closed down 99.00% at $1e-06</li>
<li><a href="https://www.benzinga.com/quote/ACNNF">AusCann Group Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ACNNF#OTC">ACNNF</a>) shares closed down 66.67% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 28.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed down 26.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed down 19.78% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed down 18.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/EAST">Eastside Distilling</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) shares closed down 17.63% at $1.13</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 12.42% at $2.79</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 10.79% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed down 9.06% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 6.20% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 5.42% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 5.41% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/MXC">Mexco Energy</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) shares closed down 5.06% at $11.07</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACNNF

CLSH

CNBX

CNPOF

CANNIBIS GROWTH OPTY CORP by Cannabis Growth Opportunity Corp.

CWWBF

GBHPF

Marijuana Stock Movers For September 9, 2024

Tilray Medical, a division of Canadian cannabis giant Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#TSX">TLRY</a>) announced on Monday a new scientific publication supported by Tilray Medical titled, Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms: A Case Series (TOMAS).
The study, consisting of patients with an average age of 52 years, examines the real-world impact of cannabinoid treatments on patients with fibromyalgia (FM) under the guidance of healthcare providers.
More precisely, the researchers take a closer look at the effects of Tilray Dried Flower THC18 on chronic pain and other FM-associated symptoms. The study examined the impact of cannabinoids on health outcomes, with a focus on pain, sleep, and quality of life.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40690381/billion-dollar-cannabis-company-closes-acquisition-of-three-us-breweries-whats-next-for-tilray">Billion-Dollar Cannabis Company Closes Acquisition Of Three US Breweries, What&#8217;s Next For Tilray</a> 
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Results</h3>
Under medical cannabis guidance and oversight, the study revealed improvements in pain levels, sleep quality and overall well-being for patients with fibromyalgia.
Additionally, a significant decrease in the need for other medications was observed, indicating that cannabinoids could be a promising and cost-effective treatment choice for this group of patients.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09092254/ccc-oct-24-banner__1_-14.gif" alt="" class="wp-image-537481" /></a></figure>
Moreover, the findings offer important insights for both the medical and scientific communities related to the potential of cannabinoids to manage chronic pain and elevate the quality of life for fibromyalgia sufferers.
"The findings of this study are encouraging and provide hope for fibromyalgia patients who are seeking effective treatments," pills José Tempero, Tilray's medical director.
&#8220;Tilray's involvement in this study underscores our unwavering commitment to advancing medical research and unlocking the full therapeutic potential of medical cannabis," added Denise Faltischek, chief strategy officer and head of international at Tilray Brands. "The TOMAS study and its positive outcomes for patients with fibromyalgia, highlights the potential of cannabinoids as a safe and effective treatment option for patients with chronic pain and associated symptoms."
Read Also:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/08/40510926/tilray-is-not-giving-up-on-cannabis-ramps-up-its-canadian-portfolio-on-heels-of-buying-four-us-b">Tilray Is Not Giving Up On Cannabis, Ramps Up Its Canadian Portfolio On Heels Of Buying Four US Breweries</a></li>
</ul>
<h3 class="wp-block-heading">TLRY Price Action</h3>
Tilray&#8217;s shares trade 2.78% higher at $1.665 per share during the pre-market session on Monday morning.

Health Care

Cannabinoid Treatment Significantly Reduces Fibromyalgia Pain And Improves Quality Of Life, New Tilray-Backed Study Finds

The cannabis market is abuzz following former President Donald Trump&#8217;s recent comments supporting cannabis legalization in Florida.&nbsp;
During a podcast interview, Trump <a href="https://www.benzinga.com/markets/cannabis/24/09/40697992/trump-talks-legal-weed-on-lex-fridman-podcast-we-can-live-with-the-marijuana">backed the state&#8217;s recreational cannabis initiative </a>and emphasized the need for a lawful and regulated framework.&nbsp;
This comes as Florida prepares to vote on a ballot initiative in November, which could reshape the cannabis landscape.
Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.
<h3 class="wp-block-heading">Top Performers And Decliners After Trump&#8217;s Comments On Marijuana </h3>
Stocks in the cannabis sector showed varied reactions on Wednesday, after <a href="https://www.benzinga.com/markets/cannabis/24/09/40677600/harris-campaign-slams-donald-trump-over-cannabis-shift-calls-it-brazen-flip-flop">Trump&#8217;s comments</a>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOLO#NYSE">YOLO</a>) AdvisorShares Pure Cannabis ETF led the gainers, climbing 3.48% to $3.27, reflecting investor optimism around potential federal changes.&nbsp;
(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CANN#OTC">CANN</a>) Trees Corporation experienced a plunge, down 99.8%, closing at $0.0001. Among the notable losers, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) Canopy Growth dropped 3.37% to $4.87, and (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) Cronos Group slipped 1.79% to $2.20.
Other stocks remained relatively stable. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) Tilray Brands fell 1.19%, ending at $1.67, and (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) Aurora Cannabis dipped 1.37% to $5.76.&nbsp;
Meanwhile, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) Sundial Growers climbed 2.53%, closing at $2.00, and (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) Trulieve Cannabis posted a 3.72% gain to $9.75, reflecting positive sentiment around these companies.
Read Also:&nbsp;<a href="https://www.benzinga.com/markets/cannabis/24/09/40712816/what-trump-learned-about-marijuana-that-desantis-did-not-and-why-the-gop-might-become-weed-frien">What Trump Learned About Marijuana That DeSantis Did Not And Why The GOP Might Become Weed-Friendly</a>
<h3 class="wp-block-heading">Stocks To Watch </h3>
<ul>
<li>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>) AdvisorShares Pure US Cannabis ETF ended the day with a slight decline of 0.31%, closing at $6.48.</li>
<li>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) Innovative Industrial Properties, a key player in cannabis real estate, dropped 0.82%, closing at $121.58, showing a more cautious response from investors.&nbsp;</li>
<li>(OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) Green Thumb Industries posted a modest gain of 0.67%, closing at $9.83, indicating optimism.&nbsp;</li>
<li>(OTC:<a class="ticker" href="https://www.benzinga.com/stock/MJNA#OTC">MJNA</a>) Medical Marijuana Inc. surged 10%, finishing at $0.0011, reflecting renewed interest despite its low price point.</li>
</ul>
Read Next:&nbsp;<a href="https://www.benzinga.com/markets/cannabis/24/09/40713542/2024-election-cannabis-swing-state-voters-back-legalization-new-poll-reveals">2024 Election &amp; Cannabis: Swing State Voters Back Legalization, New Poll Reveals</a>

Small Cap Analysis

Small Cap

Trump's Marijuana Support Could Ignite Stock Surge – Are You Positioned To Benefit?

Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#TSX">TLRY</a>) announced on Tuesday that it has completed the previously <a href="https://www.benzinga.com/markets/cannabis/24/08/40365052/billion-dollar-cannabis-firm-buys-a-brewery-four-actually-in-canadas-backyard">announced acquisition</a> of craft breweries Hop Valley Brewing Company,Terrapin Beer Co., and Revolver Brewing, from Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>).
<h3 class="wp-block-heading">Why It Matters</h3>
The acquisition bolsters Tilray&#8217;s leadership position in the U.S. craft beer market as the 5th largest craft brewer in the country and the top craft brewer in the Pacific Northwest and Georgia. Tilray is based in Canada.
This also strengthens the company's presence in Texas &#8211; the second largest beer consumption state &#8211; and expands Tilray's craft beer portfolio across key beer markets, adding 30% new beer-buying accounts.
&#8220;Tilray Brands is crafting a new future for brands in the craft beer industry,&#8221; said Irwin D. Simon, chairman and CEO of Tilray Brands. "This strategic acquisition creates additional growth opportunities for our global beverage business, which reinforces our commitment to enhancing shareholder value."
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/03105848/ccc-oct-24-banner__1_-3.gif" alt="" class="wp-image-527336" /></a></figure>
Known for brands like SweetWater Brewing and Montauk Brewing Company, Tilray earlier said it expects a 30% growth in its <a href="https://www.benzinga.com/markets/cannabis/23/09/34579077/tilrays-beer-business-expands-nationally-starting-in-this-state">beer business from this acquisition.</a>
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40036301/tilray-should-be-a-long-term-holding-in-any-global-portfolio-of-cannabis-stocks-say">‘Tilray Should Be A Long-Term Holding In Any Global Portfolio Of Cannabis Stocks,' Says Analyst</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">What's Next</h3>
"Our plan is to drive growth and maximize the potential of these brands to their fullest capacity, while maintaining our dedication to delivering high-quality products and meeting the evolving needs of our consumers," Simon added.
For Tilray, this acquisition is set to increase their beer production to 15 million cases annually. Ty Gilmore, president of Tilray Beverages in North America said he was looking forward to bringing new team members and distributors on board.
According to Michelle St. Jacques, the company's chief commercial officer, with the move Molson Coors seeks to redefine its business strategy with this deal. "This deal lets us focus our efforts on projects that will significantly grow our top-tier U.S. beer and other beverage lines."
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/06/39539050/is-tilrays-2b-valuation-just-the-beginning-analyst-sees-10b-market-opportunity-initiates-coverag">Is Tilray Really Worth $2B? Analysts Sees Path To $10B Market Opportunity</a></li>
</ul>
<h3 class="wp-block-heading">TLRY Price Action</h3>
Tilray's shares traded 1.4620% lower at $1.685 per share at the time of writing on Tuesday morning.

Billion-Dollar Cannabis Company Closes Acquisition Of Three US Breweries, What's Next For Tilray

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed up 566.67% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/HERTF">Heritage Cannabis Holding</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HERTF#OTC">HERTF</a>) shares closed up 40.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/EAST">Eastside Distilling</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) shares closed up 18.46% at $0.92</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed up 14.70% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed up 3.33% at $0.15</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed up 3.33% at $0.02</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 25.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 17.60% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed down 15.43% at $1.48</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed down 13.21% at $2.75</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 11.85% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed down 11.13% at $9.67</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">Cansortium</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 10.67% at $0.13</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed down 10.23% at $8.63</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 9.24% at $5.58</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed down 9.17% at $0.20</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed down 8.97% at $1.99</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 7.88% at $0.22</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed down 6.82% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed down 5.66% at $1.01</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed down 5.29% at $1.96</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 5.28% at $5.93</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 5.11% at $1.75</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 4.66% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CNPOF">RIV Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>) shares closed down 4.53% at $0.12</li>
<li><a href="https://www.benzinga.com/quote/ACB">Aurora Cannabis</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) shares closed down 4.48% at $6.17</li>
<li><a href="https://www.benzinga.com/quote/OGI">OrganiGram Holdings</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) shares closed down 4.31% at $1.83</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 3.39% at $57.24</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVSI

CWBHF

HERTF

LVRLF

SOLCF

Marijuana Stock Movers For August 27, 2024

WIIM

Shares of cannabis stocks are trading lower after the DEA announced a delay on its final ruling on cannabis rescheduling until after the November presidential election.

Aurora Cannabis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) has partnered with Vectura Fertin Pharma, Inc. to launch a CBD lozenge in the form of a dissolvable tablet that delivers the precise dose of cannabidiol (CBD). The new product is expected to enhance patient care by providing an alternative consumption method without psychoactive effects.
The partnership leverages Aurora&#8217;s extensive medical cannabis patient platform, said Aurora CEO Miguel Martin, who added that the company intends to broaden Canadian healthcare options with innovative products.
&#8220;Our partnership aligns with our commitment to meet Canada&#8217;s evolving healthcare needs,&#8221; Martin <a href="https://www.vecturafertinpharma.com/aurora-cannabis-and-vectura-fertin-pharma-inc-announce-commercial-collaboration/">stated</a> in a press release. 
<h3 class="wp-block-heading">NASDAQ Cannabis Titan With Global Reach</h3>
Aurora's international sales hit C$39.3 million ($28.9 million) in early 2024. This is a 31% increase year-over-year. Growth was aided by acquiring MedReleaf <a href="https://www.benzinga.com/topic/australia-cannabis">Australia</a>. Aurora now controls over 30% of <a href="https://www.benzinga.com/topic/canada-cannabis">Canada's medical marijuana </a>exports.
Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.
<h3 class="wp-block-heading">Profitability And Operational Efficiency in Cannabis </h3>
Aurora<a href="https://www.benzinga.com/quote/acb"> reported </a>increased adjusted cash gross margins rose 69% in June, up from 66% in March. However, operational expenses were 102% of adjusted cash gross profits. Still, Aurora&#8217;s net cash position rose to C$63 million. Positive operating cash flows reached C$8.4 million for the quarter.
<h3 class="wp-block-heading">Valuation And Market Position</h3>
Aurora Cannabis is valued at C$516 million with an enterprise value of C$543 million. It trades at 1.6 times its current sales, lower than competitors like Tilray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) and Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>). A recent<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40512437/aurora-cannabis-dominates-30-of-canadas-medical-marijuana-exports-will-its-bold-int"> analysis</a> done by Pablo Zuanic highlighted Aurora&#8217;s solid financial and operational performance, maintaining an attractive valuation compared to its peers.
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/08/40325566/these-3-cannabis-companies-hold-cultivation-licenses-in-germany-a-1-8b-market-opportunity">These 3 Cannabis Companies Hold Cultivation Licenses In Germany: A ~$1.8B Market Opportunity?</a>

NASDAQ Cannabis Titan, Aurora, Could Boost 31% Sales Surge With This New CBD Lozenge Partnership

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed up 33.33% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed up 28.57% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 19.05% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed up 8.01% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed up 6.54% at $1.06</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed up 6.51% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CPHRF">Cipher Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>) shares closed up 6.33% at $12.60</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed up 4.99% at $0.44</li>
<li><a href="https://www.benzinga.com/quote/GENE">Genetic Technologies</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENE#NASDAQ">GENE</a>) shares closed up 3.33% at $0.93</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed up 3.19% at $0.55</li>
<li><a href="https://www.benzinga.com/quote/CARA">Cara Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares closed up 3.16% at $0.37</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Props</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed up 3.12% at $0.59</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed down 75.00% at $0.0003</li>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed down 48.00% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 45.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed down 36.27% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/BMMJ">Body and Mind</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed down 35.71% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed down 32.12% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 20.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed down 11.27% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 9.55% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 8.37% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 7.50% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed down 6.09% at $0.15</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 5.41% at $0.23</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 3.89% at $1.86</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed down 3.04% at $2.23</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CARA

ZDPY

Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 26, 2024

<ul>
<li>NVDA</li>
<li>WAY</li>
<li>MADE</li>
<li>TLRY</li>
<li>RBLX</li>
<li>RKLB</li>
<li>LUNR</li>
<li>QQQ</li>
<li>LOT</li>
<li>ASTS</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

ASTS

LUNR

MADE

NVDA

RBLX

RKLB

Top 10 Trending Stocks On WallStreetBets As Of August 23, 2024 (Via Swaggy Stocks)

American beer maker Molson Coors ($TAP) has decided to retreat on some of its Diversity, Equity, and Inclusion (DEI) policies amid growing pressure...

Molson Coors Retreats on DEI Policies Amid Growing Activist Pressure

If you are wary of the volatility of cannabis stocks then consider the 5 tobacco, beer, and distiller/vintner companies that have major investments in the cannabis sector. Their stock returns outperformed both our MSO and LP cannabis portfolios.

Our Conservative "Cannabis" Portfolio Performed Better In August (and YTD) Than Either OUR MSO Or LP Portfolios

If you are wary of the volatility of cannabis stocks then consider the 5 tobacco, beer, and distiller/vintner companies that have major investments in the cannabis sector.

Our Conservative "Cannabis" Portfolio Performed Better In August (And YTD) Than Either Our MSO Or LP Portfolios

Look For Tilray To Keep Declining

Our LP portfolio was down 10% last week as a result of the August 26th announcement by the DEA that it had scheduled an administrative hearing for December 2nd to consider differing expert opinions on the proposal that cannabis be re-classified.

Canadian Cannabis LP Stocks Portfolio -10% W/e Sept. 6th

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Tilray (TLRY – Research Report) and Y-Mabs Therapeutics (YMAB – R...

Analysts Offer Insights on Healthcare Companies: Tilray (TLRY) and Y-Mabs Therapeutics (YMAB)

Tilray Brands Will Continue To Trend Lower

The Canadian Cannabis LP Stocks Portfolio was up +6% last week from a 10% decline w/e Sept. 6th as the negative sentiment waned surrounding the DEA's announcement that it would be having a December 2nd hearing to consider additional opinions

Cannabis LP Stocks Were +6% Last Week Vs. -10% The Previous Week

Our Conservative Cannabis Stocks Portfolio has outperformed our Canadian Cannabis LP Stocks Portfolio by more than a 3 to 1 margin on an annual basis. As such, our conservative cannabis portfolio is just that - a conservative cannabis investment.

Our Conservative Cannabis Stock Portfolio Continues To Outperform

Tilray Medical launches Redecan cannabis brand in Australia

IMBBY

YMAB

Sports

Press Releases

Shock Top and Gator Athletics Partner to Introduce First-Ever Craft Beer Sponsorship of the Florida Athletic Department

General

Solei Launches New THC Infused Sparkling Beverages and Topicals

Craft Cannabis Brand, Broken Coast, Launches Latest Artisanal Strain, 'Milk & Cookies' for Avid Indica Enthusiasts

Breckenridge Brewery Announces Latest Concert Series With Kaleo, Hippo Campus and Cassandra Lewis

Tilray Brands Completes Acquisition of Craft Beer Brands and Breweries from Molson Coors Beverage Company

Tilray Medical Supports Scientific Study on Fibromyalgia With Positive Outcomes: Effectiveness of Cannabinoids Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms

Breckenridge Brewery Unveils Oktoberfest Brew and Hosts 28th Annual Oktoberfest Festival: A Weekend of Live Music, Traditional German Cuisine, and Tasty Brews in Breckenridge, Colorado

Tilray Brands Completes Acquisition of Atwater Brewery From Molson Coors Beverage Company

Tilray Medical Launches Redecan Cannabis Brand in Australia

Shock Top Announces its Official Craft Beer Sponsorship of University of Missouri Athletics

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Tilray Brands

Tilray Brands (TLRY) Forecast

Tilray Brands (NASDAQ:TLRY) Stock, Quote.Headers.trade-ideas